1/19
Looks like no tags are added yet.
Quinidine (Quinidex)
class 1A: Na+ channel blocker (non-pacemaker)
moderate decrease in slope of phase 0 & AP peak
increase APD
also blocks K+ channels (also inhibits phase 3)
pro-arrhythmic & anticholinergic effect
QT prolongation (prolong AP duration)
MOA: inhibit K+ channels
metabolism: substrate of CYP3A4 & inhibitor of CYP2D6
Adverse Effects:
cinchonism (blurred vision, tinnitus, headache, disorientation, psychosis)
thrombocytopenia (low platelets)
Procainamide (Procan)
class 1A: Na+ channel blocker (non-pacemaker)
moderate decrease of slope of phase 0 & AP peak
increase APD
also blocks K+ channels (also inhibits phase 3)
pro-arrhythmic & anticholinergic effect
QT prolongation (prolong AP duration)
MOA: inhibit K+ channels
metabolism: acetylated in liver to N-acetyl procainamide (NAPA) → prolongs AP duration
adverse effects: systemic lupus erythromatosis (SLE)
Disopyramide (Norpace)
class 1A: Na+ channel blocker (non-pacemaker)
moderate decrease in slope of phase 0 & AP peak
increase APD
also blocks K+ channels (also inhibits phase 3)
pro-arrhythmic & MOST anticholinergic effect out of class 1A
QT prolongation (prolongs AP duration)
MOA: inhibit K+ channels
metabolism: first pass so only given IV
adverse effects: negative inotropic effect (may precipitate heart failure)
contraindications: elderly, glaucoma, heart failure
Lidocaine (Xylocaine)
class 1B: Na+ channel blocker (non-pacemaker)
weak decrease in slope of phase 0 & AP peak
slight decrease APD
high safety profile
least cardiotoxic agent among Na+ channel blockers
MOA: shorten phase 3 repolarization & AP duration
adverse effects:
nystagmus (CNS effects)
drowsiness, slurred speech, paresthesia, agitation, confusion, convulsions
Mexiletine (Mexitil)
class 1B: Na+ channel blocker (non-pacemaker)
weak decrease in slope of phase 0 & AP peak
slight decrease APD
oral from of lidocaine
MOA: shorten phase 3 repolarization & AP duration
adverse effects: nausea, vomiting, dyspepsia
Flecainide (Tambocor)
class 1C: Na+ channel blocker (non-pacemaker)
strong decrease in slope of phase 0 & AP peak
NO APD effect
MOA: dissociate slowly & minor effect on AP duration
metabolism: CYP2D6 substrate
adverse effects: blurred vision, dizziness, nausea
Propafenone (Rythmol)
class 1C: Na+ channel blocker (non-pacemaker)
strong decrease in slope of phase 0 & AP peak
NO APD effect
beta-blocking effects
MOA: dissociates slowly & minor effect on AP duration
metabolism: CYP2D6 substrate
adverse effects:
bronchospasm
blurred vision, dizziness, nausea
contraindications: asthma
Atenolol (Tenormin)
class 2: beta1 blocker (pacemaker)
decreased slope of phase 4 depolarization & prolonged repolarization at AV node
delay phase 4
block sympathetic activity
block beta-adrenergic receptors & antagonize increased sympathetic tones & high levels of NE & E
decrease HR (SA) & AV nodal conduction
beta1 selective → eliminate side effects related to lungs (cardioselective)
safe for asthma
contraindications: asthma, AV block, congestive heart failure, diabetes mellitus
Bisoprolol (Zebeta)
class 2: beta1 blocker (pacemaker)
decreased slope of phase 4 depolarization & prolonged repolarization at AV node
delay phase 4
block sympathetic activity
block beta-adrenergic receptors & antagonize increased sympathetic tones & high levels of NE & E
decrease HR (SA) & AV nodal conduction
beta1 selective → eliminate side effects related to lungs (cardioselective)
beta1 selective at low dose
contraindications: asthma, AV block, congestive heart failure, diabetes mellitus
Metoprolol (Lopressor)
class 2: beta1 blocker (pacemaker)
decreased slope of phase 4 depolarization & prolonged repolarization at AV node
delay phase 4
block sympathetic activity
block beta-adrenergic receptors & antagonize increased sympathetic tones & high levels of NE & E
decrease HR (SA) & AV nodal conduction
beta1 selective → eliminate side effects related to lungs (cardioselective)
safe for asthma
contraindications: asthma, AV block, congestive heart failure, diabetes mellitus
Esmolol (Brevibloc)
class 2: beta1 blocker (pacemaker)
decreased slope of phase 4 depolarization & prolonged repolarization at AV node
delay phase 4
block sympathetic activity
block beta-adrenergic receptors & antagonize increased sympathetic tones & high levels of NE & E
decrease HR (SA) & AV nodal conduction
beta1 selective → eliminate side effects related to lungs (cardioselective)
safe for asthma
shortest acting
contraindications: asthma, AV block, congestive heart failure, diabetes mellitus
Amiodarone (Cordarone)
class 3: K+ channel blockers (non-pacemaker)
delays repolarization (phase 3)
diminish outward potassium current during repolarization phase
prolonged AP duration without altering phase 0
can induce arrhythmias
drug notes:
iodine moiety in structure → cause thyroid dysfunction
inhibits lots of substrates (CYP1A2, CYP2A4, CYP2C9, CYP2D6)
lots of drug interactions
induce QR prolongation w/ class 1 Quinidine
precipitate bradycardia & cardiac arrest w/ beta blockers & calcium channel blockers
metabolism: 6 Ps of amiodarone
prolongs AP duration
photosensitivity
pigmentation of skin (blue)
peripheral neuropathy
pulmonary alveolitis & fibrosis
peripheral conversion of T4 to T3 inhibited
adverse effects:
long term
thyroid dysfunction (hypo OR hyperthyroidism)
pulmonary fibrosis
ocular toxicity (red-green halos, blurred vision, blindness)
optic neuritis & corneal deposits
peripheral neuropathy
hepatic toxicity
dermatologic effects - blue/gray skin
short term
more arrhythmia (bradycardia)
hypotension
nausea
vein irritant/phlebitis
photosensitivity
never give >6 months
Dronedarone (Multaq)
class 3: K+ channel blocker (non-pacemaker)
delays repolarization (phase 3)
diminish outward potassium current during repolarization phase
prolonged AP duration without altering phase 0
can induce arrhythmias
drug notes:
not as effective as Amiodarone (less drug interactions, less side effects, less lipophilic)
inhibits CYP3A4, CYP2D6
lower tissue accumulation than Amiodarone
shorter serum half life than Amiodarone
t1/2 = 4-7 days
affected by CYP3A4 inhibitors/inducers
metabolism: first pass effect
adverse effects: liver injury, QT prolongation
Sotalol (Betapace)
class 3: K+ channel inhibitor (non-pacemaker)
delays repolarization (phase 3)
diminish outward potassium current during repolarization phase
prolonged AP duration without altering phase 0
can induce arrhythmias
drug notes:
adverse effects associated with beta-blockers
metabolism:
NOT metabolized
unchanged in excretion by kidneys
adverse effects:
life threatening arrhythmia
QT prolongation
same as beta-blocker adverse effects:
AV conduction block
bradycardia
cardiac arrest
hypotension
Dofetilide (Tikosyn)
class 3: K+ channel inhibitor (non-pacemaker)
delays repolarization (phase 3)
diminish outward potassium current during repolarization phase
prolonged AP duration without altering phase 0
can induce arrhythmias
metabolism: unchanged excretion by kidneys
adverse effects: pro arrhythmia, serous arrhythmia (torsade de pointe)
Ibutilide (Corvert)
class 3: K+ channel inhibitor (non-pacemaker)
delays repolarization (phase 3)
diminish outward potassium current during repolarization phase
prolonged AP duration without altering phase 0
can induce arrhythmias
metabolism:
first pass metabolism
NOT oral
adverse effects: high risk of QT prolongation, pro arrhythmic
Diltiazem (Cardizem) & Verapamil (Calan)
class 4: non-DHP Ca2+ channel blocker (pacemaker)
block L-type calcium channels in firing cells
decrease HR (SA) & AV nodal conduction
slow down depolarization rate of phase 1 & phase 4
reduce automaticity in SA node
reduce AV conduction
drug notes:
used for anti-arrhythmic control
substrates & inhibitors of CYP3A4
drug-drug interactions
beta blockers
statins (simvastatin)
grapefruit juice may increase plasma levels of verapamil (bc inhibits metabolism so drug overdose)
adverse effects: hypotension, heart block, worsening heart failure
Adenosine (Adenocard)
has ACh-like effect on heart with greatest inhibition on AV node
IV only by rapid bolus infusion
super fast onset & super short duration
t1/2 = 8 secs
drug interactions: caffeine & theophylline antagonize adenosine in lungs
MOA: activates adenosine A1 receptors in heart → increase in ACh to slow HR
adverse effects: bronchospasm
use w caution in asthmatics
Digoxin (Lanoxin)
stimulates parasympathetic → slow HR
clinical use: when digoxin slows AV nodal conduction it controls the ventricular response in atrial fibrillation
MOA: anti-arrhythmic effects similar to Adenosine (ACh-like effect to slow HR & AV nodal conduction)
adverse effects:
ventricular tachycardia (esp w diuretics & hypokalemia)
AV depression
AV block
toxic levels can cause GI upset, altered cognition, or blurred/yellow vision
ANTIDOTE: Digibind
Magnesium
blocked Ca2+ mediated arrhythmias
give 1-2 grams IV to prevent recurrent Torsades de Pointes
can treat arrhythmias caused by digoxin intoxication
anti-arrhythmic effect from IV, NOT oral
MOA: Ca2+ antagonist